👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
Trust score 8/100
Accepting new patients
Prof
Prof Gordon Jayson
Oncology
English
12,318+
Patients seen
2
Years in practice
8
Publications
1
Languages spoken
About
Professor Gordon Jayson is a Consultant Medical Oncologist at The Christie and a Professor of Medical Oncology at the University of Manchester. He specialises in gynaecological oncology with a particular interest in ovarian and endometrial cancer.
After studying Medicine at the University of Oxford, he undertook his medical and oncology training and PhD in Manchester. In 1997 he became a Senior Lecturer at The Christie and The University of Manchester. He previously served on Cancer Research UK's New Agents Committee, the Medical Research Council's Drug and Device Development Committee and the National Clinical Trials Committee. He is now Chair of Translational Research for the Medical Research Council ICON7 as well as the Manchester Cancer Systemic Anti-Cancer Therapy Board.
Professor Jayson is actively involved in research on the development and optimisation of anti-angiogenic (anti-blood vessel) drugs for the treatment of ovarian cancer. His work has been published widely in peer-reviewed journals and he has been invited to speak at international conferences on these.
Diseases, Medical Tests and Treatments
• Chemotherapy
• Endometrial Cancer
• Gynaecological Cancers
• Ovarian Cancer
After studying Medicine at the University of Oxford, he undertook his medical and oncology training and PhD in Manchester. In 1997 he became a Senior Lecturer at The Christie and The University of Manchester. He previously served on Cancer Research UK's New Agents Committee, the Medical Research Council's Drug and Device Development Committee and the National Clinical Trials Committee. He is now Chair of Translational Research for the Medical Research Council ICON7 as well as the Manchester Cancer Systemic Anti-Cancer Therapy Board.
Professor Jayson is actively involved in research on the development and optimisation of anti-angiogenic (anti-blood vessel) drugs for the treatment of ovarian cancer. His work has been published widely in peer-reviewed journals and he has been invited to speak at international conferences on these.
Diseases, Medical Tests and Treatments
• Chemotherapy
• Endometrial Cancer
• Gynaecological Cancers
• Ovarian Cancer
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Prof Gordon Jayson
Education & training
-
2016–2022 MD · Medicine and Surgery
-
2022–2026 Residency · Oncology
-
2026–2027 Fellowship · Subspecialty training
Career & appointments
-
2026-09–2027-08 Junior consultant
Licenses & insurance
Medical licenses
— Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
AXA Healthcare Liability · 3,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 1,084 |
| Annual physical exam | 99395 | 2,754 |
| Vaccination administration | 90471 | 2,546 |
| Minor procedure (skin) | 17110 | 2,325 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 120 min | in_clinic | 810.00 EUR |
| Minor procedure (skin) | 30 min | in_clinic | 540.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 3 · i10: 13
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.2955/euroclin.2025.0 · PMID: 34458514 · cited by 76
-
European registry analysis of Oncology outcomes
DOI: 10.8238/euroclin.2024.1 · PMID: 38766969 · cited by 70
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
Society memberships
- WONCA Europe — Family Doctors — Member · since 2027
- national college of family doctors — Member · since 2027
- European Union of Medical Specialists (UEMS) — Member · since 2027
Patient reviews
- Bedside Manner
- 0.05
- Knowledge
- 0.08
- Wait Time
- 3.80
- Staff Friendliness
- 0.02
- Ease Of Appointment
- 4.00
- Value For Money
- 4.10
- Would Recommend Pct
- 4
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · professor.gordon.jayson@euroclinics.example
